相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134
Michael B. Atkins et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome
Mikiya Ishihara et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma
Alexandra Gyurdieva et al.
NATURE COMMUNICATIONS (2022)
Side-effect management of chimeric antigen receptor (CAR) T-cell therapy
M-L Schubert et al.
ANNALS OF ONCOLOGY (2021)
Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients
Takeshi Ishikawa et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells
Ana Cordeiro et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors
Mikiya Ishihara et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors
Katharina Reinhard et al.
SCIENCE (2020)
Reactive Myelopoiesis Triggered by Lymphodepleting Chemotherapy Limits the Efficacy of Adoptive T Cell Therapy
Patrick Innamarato et al.
MOLECULAR THERAPY (2020)
Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance
Daisuke Muraoka et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L. Locke et al.
LANCET ONCOLOGY (2019)
Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor
Leyuan Ma et al.
SCIENCE (2019)
Neutrophil-to-lymphocyte ratio after pazopanib treatment predicts response in patients with advanced soft-tissue sarcoma
Hiroshi Kobayashi et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2018)
Immune profiles of desmoplastic small round cell tumor and synovial sarcoma suggest different immunotherapeutic susceptibility upfront compared to relapse specimens
Mary Frances Wedekind et al.
PEDIATRIC BLOOD & CANCER (2018)
Neutrophil/lymphocyte ratio is associated with survival in synovial sarcoma
Dorian Yarih Garcia-Ortega et al.
SURGICAL ONCOLOGY-OXFORD (2018)
Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1c259 T Cells in Synovial Sarcoma
Sandra P. D'Angelo et al.
CANCER DISCOVERY (2018)
Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination
Yasushi Akahori et al.
BLOOD (2018)
Prognostic impact of the tumor immune microenvironment in synovial sarcoma
Naoki Oike et al.
CANCER SCIENCE (2018)
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Lesley Seymour et al.
LANCET ONCOLOGY (2017)
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy
Kevin A. Hay et al.
BLOOD (2017)
T-Cell Infiltration and Clonality Correlate With Programmed Cell Death Protein 1 and Programmed Death-Ligand 1 Expression in Patients With Soft Tissue Sarcomas
Seth M. Pollack et al.
CANCER (2017)
The Principles of Engineering Immune Cells to Treat Cancer
Wendell A. Lim et al.
CELL (2017)
Nanogel-Based Immunologically Stealth Vaccine Targets Macrophages in the Medulla of Lymph Node and Induces Potent Antitumor Immunity
Daisuke Muraoka et al.
ACS NANO (2014)
Current concepts in the diagnosis and management of cytokine release syndrome
Daniel W. Lee et al.
BLOOD (2014)
Adaptation and modification of the immune related response criteria (IRRC): IrRECIST
Oliver Bohnsack et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients
Shinichi Kageyama et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Establishment of animal models to analyze the kinetics and distribution of human tumor antigen-specific CD8(+) T cells
Daisuke Muraoka et al.
VACCINE (2013)
Peptide Vaccine Induces Enhanced Tumor Growth Associated with Apoptosis Induction in CD8+ T Cells
Daisuke Muraoka et al.
JOURNAL OF IMMUNOLOGY (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432
Masatoshi Aoki et al.
VACCINE (2009)
CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans
W. Nicholas Haining et al.
CLINICAL CANCER RESEARCH (2008)
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells
L Gattinoni et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
CD8+T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells
PA Antony et al.
JOURNAL OF IMMUNOLOGY (2005)
Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues
AA Jungbluth et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
T cells compete for access to antigen-bearing antigen-presenting cells
RM Kedl et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Eradication of established tumors by CD8+ T cell adoptive immunotherapy
HL Hanson et al.
IMMUNITY (2000)
分享论文
